Keywords: مهارکننده SGLT2; SGLT2; sodium-glucose cotransporter 2; SGLT2i; SGLT2 inhibitor; BDHQ; brief-type self-administered diet history questionnaire; DHQ; self-administered diet history questionnaire; GLP-1; glucagon-like peptide-1; eGFR; estimated glomerular filtration rate; B
مقالات ISI مهارکننده SGLT2 (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: مهارکننده SGLT2; cardiovascular risk; diabetic kidney disease; GLP-1 receptor agonist; SGLT2 inhibitor;
Keywords: مهارکننده SGLT2; Albuminuria; DPP-4 inhibitor; Kidney; Renal failure; SGLT2 inhibitor; Type 2 diabetes;
Keywords: مهارکننده SGLT2; Cost-effectiveness; Cost-utility study; Economic evaluation; Empagliflozin; SGLT2 inhibitor; Diabetes mellitus;
Keywords: مهارکننده SGLT2; Empagliflozin; Heart failure; SGLT2 inhibitor; Type 2 diabetes mellitus; CKD; chronic kidney disease; HF; heart failure; SGLT2; sodium glucose co-transporter 2; T2DM; type 2 diabetes mellitus;
Keywords: مهارکننده SGLT2; Canagliflozin; SGLT2 inhibitor; SGLT1 inhibitor; Kidney tumors; Pheochromocytomas; Adrenal medullary hyperplasia; Carbohydrate malabsorption;
Keywords: مهارکننده SGLT2; SGLT2 inhibitor; DPP4 inhibitor; Canagliflozin; Combination treatment; Glucagon-like peptide-1; aGLP-1; active GLP-1; ANOVA; Analysis of variance; AUC; Area under the curve; CMA; (2S)-2-Cyano-1-[trans-4-(morpholinocarbonyl)cyclohexylamino]acetylpyrrolidin
Keywords: مهارکننده SGLT2; SGLT2 inhibitor; Hyperglycemia; Hyperinsulinemia; Urinary glucose excretion; Diabetes
Keywords: مهارکننده SGLT2; SGLT2 inhibitor; Hyperglycemia; Hyperinsulinemia; Urinary glucose excretion; Diabetes
Keywords: مهارکننده SGLT2; cost-effectiveness; dipeptidyl peptidase-4 inhibitor; SGLT2 inhibitor; type 2 diabetes;
Keywords: مهارکننده SGLT2; Diabetes mellitus (DM); diabetic nephropathy (DN); hyperfiltration; glomerular filtration rate (GFR); proximal tubule; sodium/glucose cotransport; sodium/glucose cotransporter 2 (SGLT2); SGLT2 inhibitor; canagliflozin; dapagliflozin;
Keywords: مهارکننده SGLT2; diabetes; DPP-4 inhibitor; drug-drug interaction; empagliflozin; linagliptin; SGLT2 inhibitor;
Keywords: مهارکننده SGLT2; SGLT2 inhibitor; Sergliflozin-A; O-Glucoside; Pharmacokinetic stability
Effect of a SGLT2 inhibitor on the systemic and intrarenal renin-angiotensin system in subtotally nephrectomized rats
Keywords: مهارکننده SGLT2; SGLT2 inhibitor; Renin-angiotensin system (RAS); Chronic kidney disease (CKD);
Synthesis and biological evaluation of 6-hydroxyl C-aryl glucoside derivatives as novel sodium glucose co-transporter 2 (SGLT2) inhibitors
Keywords: مهارکننده SGLT2; SGLT2 inhibitor; Derivatives; Diabetes; Type-2 diabetes; C-Aryl glucosides;
Clinical risk factors predicting genital fungal infections with sodium-glucose cotransporter 2 inhibitor treatment: The ABCD nationwide dapagliflozin audit
Keywords: مهارکننده SGLT2; Dapagliflozin; SGLT2 inhibitor; Genital fungal infection; Genital mycotic infection; Thrush;
Perspectives dans le traitement pharmacologique du diabète de type 2 pour les 10 prochaines années
Keywords: مهارکننده SGLT2; Antidiabétiques oraux; combinaison thérapeutique; diabète de type 2; futur; glucagon; insulinosécrétagogue; inhibiteur des SGLT2; agoniste des récepteurs du GLP-1; Antidiabetic medication; combination therapy; GLP-1 receptor agonist; glucagon; insul
Prevention of progression of diabetic nephropathy by the SGLT2 inhibitor ipragliflozin in uninephrectomized type 2 diabetic mice
Keywords: مهارکننده SGLT2; SGLT2 inhibitor; Ipragliflozin; Hyperglycemia; Type 2 diabetes; Nephropathy;
Place des inhibiteurs des SGLT2 dans le traitement du patient diabétique de type 2
Keywords: مهارکننده SGLT2; Antidiabétiques oraux; gliflozine; inhibiteur des SGLT2; insuffisance cardiaque; protection cardiovasculaire; protection rénale; Cardiovascular protection; gliflozin; heart failure; renal protection; SGLT2 inhibitor; type 2 diabetes;
Sodium Glucose Cotransporter 2 Inhibition Combined With Cetuximab Significantly Reduced Tumor Size and Carcinoembryonic Antigen Level in Colon Cancer Metastatic to Liver
Keywords: مهارکننده SGLT2; Carcinoembryonic antigen; Cetuximab; Colon cancer; Diabetes mellitus; SGLT2 inhibitor;
SGLT2 inhibitors and renal outcomes in type 2 diabetes with or without renal impairment: A systematic review and meta-analysis
Keywords: مهارکننده SGLT2; SGLT2 inhibitor; Type 2 diabetes; Renal impairment;
Design, synthesis and biological evaluation of (2S,3R,4R,5S,6R)-5-fluoro-6-(hydroxymethyl)-2-aryltetrahydro-2H-pyran-3,4-diols as potent and orally active SGLT dual inhibitors
Keywords: مهارکننده SGLT2; Diabetes; Glucose transporter; SGLT1 inhibitor; SGLT2 inhibitor; Bioisostere; C-Aryl glucoside; QUHJWCHBJBZVQP-IDYLKPADSA-N; BILUNNIHYDMSKS-MJALHYBGSA-N; BSBHQOFIMOUJAR-MDBOPMCTSA-N; CADHWTGZCAYZEA-IDYLKPADSA-N; ADOHIJAAUMSPIL-MJALHYBGSA-N; QMNFASCAEVCTBD
Canagliflozin protects against non-alcoholic steatohepatitis in type-2 diabetic rats through zinc alpha-2 glycoprotein up-regulation
Keywords: مهارکننده SGLT2; Non-alcoholic steatohepatitis; Diabetes mellitus; SGLT2 inhibitor; Canagliflozin; Zinc-α2-glycoprotein;
Hyperglycaemic impairment of PAR2-mediated vasodilation: Prevention by inhibition of aortic endothelial sodium-glucose-co-Transporter-2 and minimizing oxidative stress
Keywords: مهارکننده SGLT2; Hyperglycaemia; Oxidative vascular dysfunction; Proteinase-activated receptor-2; SGLT2 inhibitor; Sulforaphane;
Canagliflozin potentiates GLP-1 secretion and lowers the peak of GIP secretion in rats fed a high-fat high-sucrose diet
Keywords: مهارکننده SGLT2; Diet-induced obesity; Canagliflozin; Glucagon-like peptide-1; Glucose-dependent insulinotropic polypeptide; Sodium-glucose cotransporter 1(SGLT1); SGLT2 inhibitor; DPP-IV; dipeptidyl peptidase-IV; GLP-1; glucagon-like peptide-1; GIP; Glucose-dependent i
Effect of sodium-glucose cotransporter 2 (SGLT2) inhibition on weight loss is partly mediated by liver-brain-adipose neurocircuitry
Keywords: مهارکننده SGLT2; Diabetes; Obesity; SGLT2 inhibitor; Glycogen depletion signal; Liver-brain-adipose neurocircuitry; HVx; hepatic vagotomy; SGLT2; sodium-glucose cotransporter 2; TOFO; tofogliflozin; PKA; protein kinase A;
Effects of SGLT-2 inhibitors on diabetic ketoacidosis: A meta-analysis of randomised controlled trials
Keywords: مهارکننده SGLT2; Type 2 diabetes; Meta-analysis; SGLT2 inhibitor; Ketoacidosis; Serious adverse events; Randomized clinical trials;
Effects of reducing blood pressure on renal outcomes in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME
Keywords: مهارکننده SGLT2; Blood pressure; Empagliflozin; Hypertension; Kidney; SGLT2 inhibitor; Type 2 diabetes;
Canagliflozin in Conjunction With Sulfonylurea Maintains Glycemic Control and Weight Loss Over 52 Weeks: A Randomized, Controlled Trial in Patients With Type 2 Diabetes Mellitus
Keywords: مهارکننده SGLT2; canagliflozin; cardiovascular disease; SGLT2 inhibitor; sulfonylureas; type 2 diabetes; weight loss;
Characterization and comparison of SGLT2 inhibitors: Part 3. Effects on diabetic complications in type 2 diabetic mice
Keywords: مهارکننده SGLT2; Ipragliflozin; SGLT2 inhibitor; Hyperglycemia; Diabetes; Diabetic complications;
The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats
Keywords: مهارکننده SGLT2; ACh; acetylcholine; AGE; advanced glycation end products; ALDH-2; mitochondrial aldehyde dehydrogenase; CCL-2; see MCP-1; ChIP; chromatin immunoprecipitation; COX2; cyclooxygenase-2; CRP; C-reactive protein; DHE; dihydroethidine; DHFR; dihydrofolate reduc
Beneficial metabolic actions of a stable GIP agonist following pre-treatment with a SGLT2 inhibitor in high fat fed diabetic mice
Keywords: مهارکننده SGLT2; Dapagliflozin; Diabetes; Glucose-dependent insulinotropic polypeptide (GIP); Insulin secretion; SGLT2 inhibitor;
The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db/db mice both as monotherapy and in combination with linagliptin
Keywords: مهارکننده SGLT2; DIO; diet-induced obese; DPP; dipeptidyl peptidase; FAS; fatty acid synthase; FPG; fasting plasma glucose; GDR; glucose disposal rate; HbA1c; glycated hemoglobin; HGP; hepatic glucose production; HPRT; hypoxanthine phosphoribosyltransferase; OGTT; oral gl
Fed and Fasted Single-dose Assessment of Bioequivalence of Dapagliflozin and Metformin Extended-release Fixed-dose Combination Tablets Relative to Single-component Dapagliflozin and Metformin Extended-release Tablets in Healthy Subjects
Keywords: مهارکننده SGLT2; bioequivalence; dapagliflozin; fixed-dose combination; metformin extended release; SGLT2 inhibitor; type 2 diabetes mellitus;
Protective effects of SGLT2 inhibitor luseogliflozin on pancreatic β-cells in obese type 2 diabetic db/db mice
Keywords: مهارکننده SGLT2; Pancreatic β-cells; SGLT2 inhibitor; β-cell mass and function;
Original ResearchSafety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes
Keywords: مهارکننده SGLT2; adverse drug event; hypoglycemia; ketoacidosis; safety; SGLT2 inhibitor;
Effects of reducing blood pressure on cardiovascular outcomes and mortality in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME
Keywords: مهارکننده SGLT2; Blood pressure; Diuretic; Empagliflozin; Hypertension; SGLT2 inhibitor; Type 2 diabetes;
C-Aryl glucoside SGLT2 inhibitors containing a biphenyl motif as potential anti-diabetic agents
Keywords: مهارکننده SGLT2; SGLT2 inhibitor; Type 2 diabetes; C-Aryl glucoside; Biphenyl
Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats
Keywords: مهارکننده SGLT2; Ipragliflozin l-proline (PubChem CID: 57339444); Pioglitazone (PubChem CID: 4829); SGLT2 inhibitor; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Choline-deficient and amino acid-defined diet;
Short-term selective alleviation of glucotoxicity and lipotoxicity ameliorates the suppressed expression of key β-cell factors under diabetic conditions
Keywords: مهارکننده SGLT2; Glucotoxicity; Lipotoxicity; SGLT2 inhibitor; Fibrate; islet β-cell dysfunction; Insulin transcription factors;
Synthesis of novel N-glycoside derivatives via CuSCN-catalyzed reactions and their SGLT2 inhibition activities
Keywords: مهارکننده SGLT2; N-Glycoside; Heterocycle; Coupling reaction; SGLT2 inhibitor; Carbohydrate;
Bioequivalence, Food Effect, and SteadyâState Assessment of Dapagliflozin/Metformin Extendedârelease Fixedâdose Combination Tablets Relative to Singleâcomponent Dapagliflozin and Metformin Extendedârelease Tablets in Healthy Subjects
Keywords: مهارکننده SGLT2; bioequivalence; dapagliflozin; metformin XR; pharmacokinetics; SGLT2 inhibitor; type 2 diabetes mellitus;
Pharmacokinetics of Empagliflozin and Pioglitazone After Coadministration in Healthy Volunteers
Keywords: مهارکننده SGLT2; diabetes; drug-drug interaction; SGLT2 inhibitor; thiazolidinedione;
Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes
Keywords: مهارکننده SGLT2; Empagliflozin; Glycaemic control; Metformin; SGLT2 inhibitor; Sulphonylurea;
Effect of Renal Impairment on the Pharmacokinetics, Pharmacodynamics, and Safety of Empagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, in Japanese Patients With Type 2 Diabetes Mellitus
Keywords: مهارکننده SGLT2; empagliflozin; Japanese patients; pharmacodynamics; pharmacokinetics; renal impairment; SGLT2 inhibitor;
C-Glucosides with heteroaryl thiophene as novel sodium-dependent glucose cotransporter 2 inhibitors
Keywords: مهارکننده SGLT2; Type 2 diabetes; SGLT2 inhibitor; Thiophene; Glucoside; Canagliflozin;
Synthesis and biological evaluation of C-glucosides with azulene rings as selective SGLT2 inhibitors for the treatment of type 2 diabetes mellitus: Discovery of YM543
Keywords: مهارکننده SGLT2; Type 2 diabetes mellitus; SGLT2 inhibitor; Azulene; YM543;
Design, synthesis and biological activity of cyclohexane-bearing C-glucoside derivatives as SGLT2 inhibitors
Keywords: مهارکننده SGLT2; Synthesis; C-Glucoside; SGLT2 inhibitor; Urinary glucose excretion; Cyclohexane-bearing
A cell-based fluorescent glucose transporter assay for SGLT2 inhibitor discovery
Keywords: مهارکننده SGLT2; SGLT2 inhibitor; NBDG; Type 2 diabetes mellitus; Kidney
Lack of Clinically Relevant Drug–Drug Interaction Between Empagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, and Verapamil, Ramipril, or Digoxin in Healthy Volunteers
Keywords: مهارکننده SGLT2; digoxin; drug–drug interaction; empagliflozin; ramipril; SGLT2 inhibitor; type 2 diabetes; verapamil